{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The Combination therapy portion of the study was terminated prior to full enrollment for futility. Enrollment was halted as preliminary antitumor activity of selinexor was assessed by the Sponsor to be insufficiently competitive compared to currently available or anticipated future treatments."},"pointOfContact":{"email":"clinicaltrials@karyopharm.com","organization":"Karyopharm Therapeutics Inc","phone":"(888) 209-9326","title":"Karyopharm Medical Information"}}